Omzo vs CoreAgeRx: Pricing, Compounded Drugs, Clinician Review
Quick verdict: Omzo focuses on clinician-guided, personalized compounded semaglutide with a starting price of $179, while CoreAgeRx emphasizes flat monthly pricing with semaglutide at $79 per month and tirzepatide at $129 per month. This comparison highlights pricing model, compounded versus branded prescriptions, clinician review and visit format, dosing details, and regulatory notes for Omzo vs CoreAgeRx.
See Omzo plans and starting price
Head-to-head: Omzo vs CoreAgeRx on pricing model
Price structure is one of the clearest contrasts. Omzo lists semaglutide starting at $179 and tirzepatide starting at $279 with clinician-guided, personalized compounded programs. CoreAgeRx promotes “Same Price. Every Month.” with semaglutide at $79 per month and tirzepatide at $129 per month and says there is no membership fee and no price hikes.
Compounded medications and regulatory status
The providers differ in how medication is delivered and described. Omzo’s primary program provides access to compounded medications prepared by state-licensed sterile compounding pharmacies and explicitly states these compounded drugs are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. CoreAgeRx notes that medication-specific approval status must be confirmed and cautions that branded and compounded products are not interchangeable; it also states that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
Clinician review, visit format, and enrollment
Both emphasize clinician involvement but present it differently. Omzo connects customers with licensed medical providers who determine eligibility and provide clinician-guided plans reviewed by licensed U.S. providers. Omzo clarifies that clinical services are provided by third party networks of U.S.-licensed clinicians who determine eligibility and make final prescribing determinations.
CoreAgeRx advertises a 3-minute online visit and clinician review, and states treatment is available only when a licensed clinician determines it is medically appropriate. CoreAgeRx also highlights no insurance required for the visit. Neither source supplies a detailed vetted protocol for follow up frequency beyond these statements.
Start CoreAgeRx 3-minute visit
Dosing and product options
Omzo lists semaglutide and tirzepatide programs and notes clinicians may prescribe either compounded medications or write prescriptions for branded medications like Ozempic or Wegovy, but Omzo does not sell, dispense, or ship branded medications. CoreAgeRx specifies dosing ranges on its landing page: tirzepatide up to 7.5 mg and semaglutide up to 1.0 mg, presented with flat monthly pricing. Exact availability by dose, state, and clinician discretion are subject to live offer and clinician determination.
Regulatory and enrollment cautions
Both providers advise confirming eligibility, medication, total cost, renewal terms and state availability before enrollment. Omzo explicitly states compounded medications are not FDA-approved and that Omzo is not a medical practice; the assessment on Omzo does not create a doctor patient relationship and providers make final prescribing decisions. CoreAgeRx similarly indicates medication-specific approval status must be confirmed and that treatment is available only when a licensed clinician determines it is medically appropriate.
Comparison table: Omzo vs CoreAgeRx
| Criteria | Omzo | CoreAgeRx |
|---|---|---|
| Price example | Semaglutide starting at $179; tirzepatide starting at $279 | Semaglutide $79 per month; tirzepatide $129 per month |
| Pricing model | Personalized clinician-guided, per program pricing | Flat monthly pricing, “Same Price. Every Month.” |
| Medication type | Compounded medications program; providers may also prescribe branded meds (patient fills separately) | Offers compounded or branded depending on clinician; dosing up to specified limits |
| Dosing limits stated | Semaglutide and tirzepatide offered; doses determined by clinicians | Tirzepatide up to 7.5 mg; semaglutide up to 1.0 mg listed |
| Clinician interaction | Clinician-guided plans reviewed by licensed U.S. providers; third party clinician networks | 3-minute online visit; treatment subject to licensed clinician determination |
| Regulatory note | Compounded drugs not FDA-approved and not reviewed by FDA | Compounded drugs not FDA-approved noted; approval status must be confirmed |
How they differ most
Three distinctive differences stand out for Omzo vs CoreAgeRx: price presentation and structure, the prominence and framing of compounded medication programs with regulatory disclaimers, and the advertised patient interaction format. Omzo emphasizes personalized, clinician-guided, compounded programs with stated starting prices and clear regulatory language about compounded products. CoreAgeRx emphasizes predictable flat monthly costs, specific dose caps advertised on the landing page, and a brief 3-minute online visit.
Lock in CoreAgeRx flat monthly price
Conclusion: Omzo vs CoreAgeRx
In summary, Omzo vs CoreAgeRx diverge on pricing approach and program structure. Use the primary keyword when deciding which matters more to you: Omzo vs CoreAgeRx. If you prioritize clinician-guided, personalized compounded programs with per-program pricing and clear statements that compounded drugs are not FDA-approved, Omzo presents that model with semaglutide starting at $179. If you prioritize predictable monthly billing with advertised semaglutide at $79 per month or tirzepatide at $129 per month and a short online visit, CoreAgeRx emphasizes flat monthly pricing.
Explore Omzo clinician-guided options
Choose one if…
- Choose Omzo if you want clinician-guided, personalized compounded semaglutide or tirzepatide programs and accept that compounded medications are not FDA-approved and providers will determine eligibility and prescriptions.
- Choose CoreAgeRx if you want flat monthly pricing advertised as the same price every month with semaglutide at $79 per month or tirzepatide at $129 per month and a short 3-minute online visit, subject to clinician determination and confirmation of medication status.